Prompt treatment of sHLH with broad immunosuppressive or immunomodulatory therapies such as glucocorticoids, cyclosporine, intravenous gamma globulin, anti-IL-6 and anti-IL-1 agents, or chemotherapeutics is important for favorable outcomes. However, use of immunosuppressant therapy in COVID-19 patients must be done cautiously, as co-infections can occur with COVID-19, and such infections have been associated with severity of SARS-CoV-2 as well as poor outcomes [8]. Here, IL6 is linked to COVID-19.